Clinical trial
Efficacy Study of Sargramostim in the Retreatment of Patients Who Have Crohn's…
NCT00206713 · Genzyme, a Sanofi Company, Industry · Terminated
Key facts
| NCT number | NCT00206713 |
|---|---|
| Title | Efficacy Study of Sargramostim in the Retreatment of Patients Who Have Crohn's Disease Who Have Previously Responded to Treatment With Sargramostim |
| Official title | Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Retreatment Study of Sargramostim (Leukine®) in Patients With Active Crohn's Disease and Prior Treatment Response to Sargramostim |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Crohn Disease |
| Intervention type | Drug |
| Interventions | Sargramostim (Leukine), Placebo |
| Enrollment | 264 |
| Start date | Jul 1, 2004 |
| Primary completion | Oct 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | Sep 21, 2005 |
| Last update posted | Dec 4, 2013 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: